Novartis AG (NYSE:NVS) – Research analysts at Leerink Swann lowered their Q4 2016 EPS estimates for shares of Novartis AG in a report released on Monday. Leerink Swann analyst S. Fernandez now anticipates that the brokerage will post earnings of $1.10 per share for the quarter, down from their previous forecast of $1.11. Leerink Swann also issued estimates for Novartis AG’s Q1 2017 earnings at $1.14 EPS, Q2 2017 earnings at $1.20 EPS, Q3 2017 earnings at $1.22 EPS, Q4 2017 earnings at $1.24 EPS, FY2017 earnings at $4.79 EPS, FY2018 earnings at $5.36 EPS, FY2019 earnings at $5.63 EPS, FY2020 earnings at $5.72 EPS and FY2021 earnings at $6.17 EPS.
A number of other research firms have also weighed in on NVS. J P Morgan Chase & Co reaffirmed a “neutral” rating on shares of Novartis AG in a research report on Thursday, January 19th. Jefferies Group LLC reaffirmed a “buy” rating on shares of Novartis AG in a research report on Sunday, October 16th. TheStreet lowered Novartis AG from a “buy” rating to a “hold” rating in a research report on Wednesday, September 28th. Credit Suisse Group lowered Novartis AG from an “outperform” rating to a “neutral” rating in a research report on Wednesday, January 11th. Finally, Berenberg Bank lowered Novartis AG from a “buy” rating to a “hold” rating in a research report on Tuesday, January 17th. Two research analysts have rated the stock with a sell rating, twelve have given a hold rating and three have issued a buy rating to the company’s stock. Novartis AG currently has an average rating of “Hold” and a consensus price target of $85.18.
Novartis AG (NYSE:NVS) traded up 2.6273% on Wednesday, reaching $71.8699. The company’s stock had a trading volume of 4,072,761 shares. The company’s 50 day moving average price is $71.56 and its 200-day moving average price is $76.20. Novartis AG has a 12-month low of $66.93 and a 12-month high of $83.58. The stock has a market cap of $170.73 billion, a PE ratio of 25.3420 and a beta of 0.68.
Novartis AG (NYSE:NVS) last posted its quarterly earnings data on Wednesday, January 25th. The company reported $1.12 earnings per share for the quarter, hitting the Thomson Reuters’ consensus estimate of $1.12. Novartis AG had a return on equity of 15.25% and a net margin of 13.98%. The business had revenue of $12.32 billion for the quarter, compared to analysts’ expectations of $12.34 billion. During the same quarter in the previous year, the firm earned $1.14 earnings per share. The business’s revenue was down 1.6% on a year-over-year basis.
Several hedge funds have recently bought and sold shares of NVS. The Manufacturers Life Insurance Company purchased a new position in Novartis AG during the third quarter worth about $304,776,000. CGOV Asset Management purchased a new position in Novartis AG during the third quarter worth about $82,650,000. Parnassus Investments CA increased its position in Novartis AG by 22.9% in the third quarter. Parnassus Investments CA now owns 4,278,005 shares of the company’s stock worth $337,791,000 after buying an additional 796,109 shares during the period. Aristotle Capital Management LLC increased its position in Novartis AG by 31.9% in the second quarter. Aristotle Capital Management LLC now owns 2,736,946 shares of the company’s stock worth $225,825,000 after buying an additional 662,285 shares during the period. Finally, FMR LLC increased its position in Novartis AG by 65.6% in the second quarter. FMR LLC now owns 1,208,384 shares of the company’s stock worth $99,704,000 after buying an additional 478,679 shares during the period. 9.84% of the stock is owned by institutional investors and hedge funds.
About Novartis AG
Novartis AG is a holding company. The Company specializes in the research, development, manufacturing and marketing of a range of healthcare products led by pharmaceuticals, including eye care products. Its portfolio includes medicines, eye care and generic pharmaceuticals. The Company’s segments include Pharmaceuticals, Alcon and Sandoz.